SPEC — SpectraCure AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK24.82m
- SEK26.10m
- SEK0.87m
Brief: SpectraCure Gets China Patent for New Treatment System
Brief: SpectraCure Q2 Net Loss After Tax At SEK 6.8 Million
Brief: Spectracure Gets Canadian Patent Approval
Brief: SpectraCure Says Rights Issue Subscribed To 50.6%
Brief: SpectraCure Announces Prelim Results Of Rights Issue
Brief: Spectracure Announces Rights Issue Of Up To 1.14 Bln Units For Sek 34.2 Bln
Brief: Spectracure Appoints Fata Mrsic As CFO
Brief: Spectracure Q1 Net Loss After Tax SEK 6.1 Mln
Brief: Spectracure Q4 Loss After Tax Widens To SEK 7.56 Mln
Brief: Spectracure Signs Agreement With Rostock Hospital For Prostate Cancer Study
Brief: Spectracure To Get SEK 31.3 Mln If All TO5 Warrants Utilized
Brief: Spectracure Q3 Net Loss SEK 35 Mln
Brief: Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
Brief: Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
Brief: Spectracure Q-Pro Patent Approved In Japan
Brief: Spectracure Gets Approval To Commence Clinical Trial
Brief: Spectracure Appoints Johannes Swartling As CEO
Brief: Spectracure Reports Positive Results In Prostate Cancer Study
Brief: Spectracure Q2 Loss After Tax SEK 7.2 Mln